fangchinoline has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, EJ; Choi, SU; Jung, NP; Kim, HS; Kim, KH; Kim, S; Lee, CO; Park, SH; Park, WK; Zhang, YH | 1 |
| Chen, GY; Chen, YH; Chu, PY; Hsieh, CL; Hsu, WY; Wang, K; Winardi, D; Wu, YC; Yang, JC | 1 |
2 other study(ies) available for fangchinoline and Cancer of Ovary
| Article | Year |
|---|---|
The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cell Survival; Colorectal Neoplasms; Dactinomycin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Isoquinolines; Molecular Structure; Ovarian Neoplasms; Verapamil | 1998 |
Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model.
Topics: Animals; Aurora Kinase A; Benzylisoquinolines; Cell Line, Tumor; Cisplatin; DNA Adducts; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Molecular; Molecular Docking Simulation; Ovarian Neoplasms; Protein Conformation; Xenograft Model Antitumor Assays | 2022 |